NASDAQ: SABS - SAB Biotherapeutics, Inc.

Rentabilität für sechs Monate: +46.15%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan SAB Biotherapeutics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

weitere details
The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2021-02-09
ISIN US78397T1034
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sabbiotherapeutics.com
Цена ао 4.17
Preisänderung pro Tag: 0% (4.18)
Preisänderung pro Woche: -10.11% (4.65)
Preisänderung pro Monat: +41.69% (2.95)
Preisänderung über 3 Monate: +62.65% (2.57)
Preisänderung über sechs Monate: +46.15% (2.86)
Preisänderung pro Jahr: +507.56% (0.688)
Preisänderung über 3 Jahre: -51.34% (8.59)
Preisänderung über 5 Jahre: 0% (4.18)
Preisänderung über 10 Jahre: 0% (4.18)
Preisänderung seit Jahresbeginn: +22.22% (3.42)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 1.75 8
P/BV 0.0684 10
P/E 0 0
EV/EBITDA 1.36 10
Gesamt: 6

Effizienz

Name Bedeutung Grad
ROA, % -50.27 0
ROE, % -73.64 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.1721 10
Gesamt: 9.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -34.15 0
Rentabilität Ebitda, % 364.33 10
Rentabilität EPS, % 3428.04 10
Gesamt: 8
Weitere Details

Institutionen Volumen Aktie, %
Marshall Wace LLP 4585282 49.7
RA Capital Management, L.P. 2374081 25.73
COMMODORE CAPITAL LP 1831746 19.86
RTW Investments LP 917828 9.95
BVF Inc. 917828 9.95
Sessa Capital IM, L.P. 458457 4.97
Vanguard Group Inc 99614 1.08
First Premier Bank 80754 0.88
Pathstone Holdings, LLC 50651 0.55
Geode Capital Management, LLC 35636 0.39

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
iShares Micro-Cap ETF 0.00541 17.09 1.54048



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Samuel J. Reich CEO & Executive Chairman 363.2k 1975 (50 Jahre)
Dr. Eddie Joe Sullivan Ph.D. Co-Founder, President & Director 402.56k 1966 (59 Jahre)
Ms. Christine E. Hamilton M.B.A. Co-Founder & Independent Director 25k 1956 (69 Jahre)
Dr. Alexandra Kropotova M.B.A., M.D. Executive VP & Chief Medical Officer 774.45k 1973 (52 Jahr)
Dr. Edward D. Hamilton D.V.M. Co-Founder & Board Observer N/A
Dr. Christoph Bausch M.B.A., Ph.D. Executive VP & COO 443.2k 1971 (54 Jahr)
Dr. Carlos N. Carillo Ph.D. Senior Vice President of Regulatory Affairs N/A
Mr. Mark W. Conley Interim Chief Financial Officer

Adresse: United States, Sioux Falls. SD, 2100 East 54th Street North - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.sabbiotherapeutics.com